Crossmark

GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations

Crossref DOI link: https://doi.org/10.1038/s41375-019-0399-7

Published Online: 2019-02-12

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sportoletti, Paolo https://orcid.org/0000-0002-5630-9862
Celani, Letizia

Varasano, Emanuela

Rossi, Roberta

Sorcini, Daniele

Rompietti, Chiara

Strozzini, Francesca

Del Papa, Beatrice

Guarente, Valerio

Spinozzi, Giulio

Cecchini, Debora

Bereshchenko, Oxana

Haferlach, Torsten

Martelli, Maria Paola

Falzetti, Franca

Falini, Brunangelo
License Information

Text and Data Mining valid from 2019-02-12
More Information

Article History

Received: 19 September 2018

Revised: 30 December 2018

Accepted: 21 January 2019

First Online: 12 February 2019

Compliance with ethical standards

:

: BF applied for a patent on the clinical use of NPM1 mutants. The other authors declare that they have no conflict of interest.